GraphCMS Joins the MACH Alliance to Federate Composable Architectures
24.11.2021 20:00:00 EET | Business Wire | Press release
GraphCMS — the Berlin-based company behind the headless GraphQL content federation platform that helps leading companies unify the content layer by federating business-critical APIs — announced today that they have joined the MACH alliance, an independent group of tech companies advocating for an open and best-of-breed enterprise technology ecosystem. As part of the MACH alliance, GraphCMS will work closely with the other members to guide companies on how they can benefit from a lean and modular approach to enterprise technologies, by adopting MACH (microservices, API-first, Cloud-native SaaS, and Headless) architectures.
Liberating data effectively from legacy and third-party systems is a key challenge for digitally-driven enterprises as they strive towards creating immersive, high-performance digital experiences. GraphCMS’s leading content management capabilities and novel approach to remote data fetching from external systems such as other MACH vendors — dubbed “Content Federation” — enables microservices to talk to each other, helping organizations deliver cutting-edge digital experiences across platforms, from streaming services to innovative new eCommerce platforms in a fraction of the time. Companies can build complex applications while aggregating their data from multiple sources into a single API, effectively eliminating content silos and “API Sprawl”.
“The MACH alliance’s ethos of encouraging companies in adopting modern, composable microservices rather than monolithic suites is extremely aligned with our own vision at GraphCMS, as we work with our customers in modernizing their stacks using best-of-breed solutions”, explains Christopher Kühn, CCO at GraphCMS.
Already supporting companies like Telenor, Burrow, 2U Inc., and Prym in their ambitious initiatives to deliver better digital experiences to millions of consumers via Content Federation, GraphCMS aims to accelerate the enterprise adoption of MACH compliant software architectures as the “glue” that federates them together into a single GraphQL API.
“We’re thrilled to be joining the MACH Alliance. Their approach represents the future of software, where companies are in charge of defining composable tech stacks that are perfectly aligned with scaling their business model, rather than adapting to inflexible monolithic suites”, adds Ronak Ganatra, VP of Marketing at GraphCMS.
About GraphCMS
GraphCMS is the first enterprise-class headless content management and federation platform that enables data unification from multiple APIs. With the industry's most versatile GraphQL content APIs and a novel approach in external data sourcing via API extensions, the content platform enables use cases beyond simple headless CMS' capabilities. Enterprise customers see GraphCMS as a database highly optimized for structured content while giving content creators the tools to build their ultimate content pipeline. GraphCMS is developed by GraphCMS GmbH, headquartered in Berlin, Germany, and is currently enabling over 50,000 teams across the world to rapidly build and deliver tomorrow’s omnichannel digital experiences at scale.
About the MACH Alliance
The MACH Alliance is a [501(c)(6)] non-profit organization, governed by an independent board and does not endorse specific vendors, members, or otherwise. The Alliance was formed in June 2020 to help enterprise organizations navigate the complex modern technology landscape. It aims to guide and show the business advantage of open tech ecosystems that are Microservices based, API-first, Cloud-native, and Headless. All MACH Alliance members meet certification principles that are published on the website.
Founding members include Amplience, commercetools, Contentstack, EPAM Systems, and Valtech. The MACH Alliance welcomes technology companies and individual industry experts who share the same vision for the future. Learn more at machalliance.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005030/en/
Contact information
Press Contact:
Emily Nielsen
press@graphcms.com
+49 30 28879641
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom